Table 2:

Event rates of primary and secondary outcomes in a matched cohort of patients with diabetic retinopathy prescribed ARBs and ACE inhibitors

Outcome	ARB cohort			ACE inhibitor cohort (reference)			Hazard ratio (95% CI)
	No. of events	No. of person-years	Incidence rate*	No. of events	No. of person-years	Incidence rate*
All-cause death	1 421	54 620	26.0	1 500	54 129	27.7	0.94 (0.87–1.01)
Major adverse cardiac events	944	52 004	18.2	978	51 409	19.0	0.95 (0.87–1.04)
Myocardial infarction	317	53 867	5.9	306	53 501	5.7	1.03 (0.88–1.20)
Ischemic stroke	685	52 664	13.0	720	51 966	13.9	0.94 (0.85–1.04)
Cardiovascular death	417	54 581	7.6	408	54 103	7.5	1.01 (0.88–1.16)
Hospital admission with acute kidney injury	671	53 311	12.6	656	52 829	12.4	1.01 (0.91–1.13)
Hospital admission with hyperkalemia	320	53 892	5.9	314	53 325	5.9	1.01 (0.86–1.18)

Note: ACE = angiotensin-converting enzyme, ARB = angiotensin II receptor blocker, CI = confidence interval.

^*Per 1000 person-years.